December 20, 2017 05:34 AM ESTUpdated December 31, 03:01 PM
Financing

Park­er In­sti­tute-al­lied Tes­sa grabs an $80M round for its next-gen can­cer cell ther­a­pies

John Carroll

Editor & Founder

Last sum­mer the Park­er In­sti­tute for Can­cer Im­munother­a­py raised eye­brows in R&D cir­cles with its an­nounce­ment that it was al­ly­ing it­self with a lit­tle …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times